Literature DB >> 15987349

A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients.

Beatrice Diedrich1, Mats Remberger, Agneta Shanwell, Britt-Marie Svahn, Olle Ringdén.   

Abstract

BACKGROUND: The impact of lowering the platelet (PLT) count threshold for prophylactic PLT transfusion on bleeding and PLT use in allogeneic hematopoietic progenitor cell (HPC) transplant recipients is a matter of debate. STUDY DESIGN AND METHODS: In 166 patients, randomly assigned to receive prophylactic PLT transfusion at a trigger level less than 10 x 10(9) PLTs per L (T10; n = 79) or less than 30 x 10(9) per L (T30; n = 87), the number of PLT and red blood cell (RBC) transfusions given and the number of hemorrhagic events (WHO Grades 2-4) were recorded.
RESULTS: No significant differences were found between the two groups regarding the clinical outcome variables (i.e., bacteremia, engraftment, graft-vs.-host disease [GVHD], hospital stay, death, and survival) or in the median total number of RBC transfusions given. The incidence, in Group T10 18 percent (14/79) and in Group T30 15 percent (13/87), as well as the type of bleeding were comparable. No deaths were attributed to hemorrhages. The number of PLT units transfused, however, was significantly lower in Group T10 (median, 4; range, 0-32), than in Group T30 (median, 10; range, 0-48; p < 0.001). Apart from the trigger level, the day of engraftment, the presence of acute GVHD, or bacteremia also affected the number of PLT transfusions.
CONCLUSION: A prophylactic PLT transfusion trigger level of less than 10 x 10(9) PLTs per L instead of less than 30 x 10(9) PLTs per L in allogeneic HPC transplant recipients was found to be safe and resulted in a decreased use of PLTs.

Entities:  

Mesh:

Year:  2005        PMID: 15987349     DOI: 10.1111/j.1537-2995.2005.04157.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  20 in total

Review 1.  [Therapy with blood products].

Authors:  S Petros
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-01-29       Impact factor: 0.840

Review 2.  Indications for platelet transfusion in patients with thrombocytopenia.

Authors:  Jerry E Squires
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

3.  Microfluidic Flow Chambers Using Reconstituted Blood to Model Hemostasis and Platelet Transfusion In Vitro.

Authors:  Britt Van Aelst; Hendrik B Feys; Rosalie Devloo; Philippe Vandekerckhove; Veerle Compernolle
Journal:  J Vis Exp       Date:  2016-03-19       Impact factor: 1.355

4.  Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants.

Authors:  Melhem Solh; Claudio Brunstein; Shanna Morgan; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-14       Impact factor: 5.742

5.  Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH.

Authors:  Tzu-Fei Wang; Robert S Makar; Darko Antic; Jerrold H Levy; James D Douketis; Jean M Connors; Marc Carrier; Jeffrey I Zwicker
Journal:  J Thromb Haemost       Date:  2020-12       Impact factor: 5.824

6.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Intensive Care Med       Date:  2017-01-18       Impact factor: 17.440

Review 7.  How well do platelets prevent bleeding?

Authors:  Darrell J Triulzi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 8.  A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation.

Authors:  James L Gajewski; Viviana V Johnson; S Gerald Sandler; Antoine Sayegh; Thomas R Klumpp
Journal:  Blood       Date:  2008-06-26       Impact factor: 22.113

9.  An audit of platelet transfusion indications in acute leukaemia patients: six-year experience at an Academic Centre.

Authors:  José C Jaime-Pérez; Gerardo García-Salas; Grecia A Turrubiates-Hernández; Dalila M Alvarado-Navarro; Luis J Marfil-Rivera; David Gómez-Almaguer
Journal:  Blood Transfus       Date:  2020-11-03       Impact factor: 3.443

10.  Utilization of blood and components in a tertiary care hospital.

Authors:  Dushyant Singh Gaur; Gita Negi; Neena Chauhan; Anuradha Kusum; Sabina Khan; Ved Prakash Pathak
Journal:  Indian J Hematol Blood Transfus       Date:  2009-11-12       Impact factor: 0.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.